Skip to content

Association of APOE Gene Polymorphisms with Gut Microbiota and Hippocampal Functional Connectivity in Mild Cognitive Impairment

Association of APOE Gene Polymorphisms with Gut Microbiota and Hippocampal Functional Connectivity in Mild Cognitive Impairment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115811
Enrollment
Unknown
Registered
2025-12-31
Start date
2025-06-17
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive

Interventions

Normal cognitive control group:None

Sponsors

Fujian University of Traditional Chinese Medicine Rehabilitation Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for Mild Cognitive Impairment (MCI) or cognitively normal older adults with a Montreal Cognitive Assessment (MoCA) score =26; 2. Aged >=60 years; right-handed (assessed using the Edinburgh Handedness Inventory); 3. Provide informed consent and voluntarily participate.

Exclusion criteria

Exclusion criteria: 1.Participants with a score >=9 on the Short Geriatric Depression Scale (GDS-15). 2.Patients diagnosed with dementia of any etiology. 3.Individuals with cognitive impairment caused by other conditions, including medication use (e.g., antipsychotics, benzodiazepines), intoxication, inflammatory cerebrovascular disease, encephalitis, brain tumors, traumatic brain injury, epilepsy, or Parkinson’s disease. 4.Patients with severe cardiac, hepatic, or renal failure, malignant tumors, or other major systemic illnesses. 5.Individuals with severe visual, auditory, or speech impairments that preclude valid cognitive assessment. 6.Participants with contraindications to MRI scanning (e.g., cardiac pacemakers, coronary stents, fixed dental prostheses, metal implants, claustrophobia, or febrile conditions). 7.Individuals who have taken prokinetic agents, laxatives, or other medications affecting gastrointestinal motility within the past month; or who have used antibiotics, probiotics, or prebiotics within the past month. 8.Patients with gastrointestinal diseases such as irritable bowel syndrome, ulcerative colitis, Crohn’s disease, or intestinal tumors. 9.Patients with poorly controlled hypertension (systolic BP >160 mmHg or diastolic BP >100 mmHg despite medication). 10.Participants currently enrolled in other clinical trials that may interfere with the outcomes of this study.

Design outcomes

Primary

MeasureTime frame
Cognitive impairment;Fuzhou Version of the Montreal Cognitive Assessment (MoCA);Wechsler Memory Scale Test;Rey Auditory Verbal Learning Test,RAVLT;Rey-Osterrieth Complex Figure Test ,ROCF;Digital symbols transformation test,DST;Trail Making Test B,TMT B;Stroop Color-Word Card Test;Food frequency questionnaire,FFQ25;24-Hour Dietary Recall Scale;

Countries

China

Contacts

Public ContactWu Lixin

Rehabilitation Hospital Affiliated to Fujian University of Traditional Chinese Medicine

wulixinxixixi@126.com+86 136 0593 8055

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026